In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.
The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
A court ruling doesn’t permit schools to “force-vaccinate” students, it addresses civil liability for accidentally ...
The Independent on MSN18h
Lab-made ‘mirror bacteria’ could endanger all life on earth, scientists warnBut doing so still requires “substantial breakthroughs in synthetic cell research”, the scientists said. HIV gamechanger: Lenacapavir study participant explains Although the capability to engineer ...
El Mundo on MSN13h
Drug that protects against HIV with two 'shots' a year, discovery of the year for 'Science'Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
The drug, named lenacapavir, targets the structure and function of HIV's capsid protein. It protects people for 6 months with each shot. Unlike mainstay HIV drugs that disrupt viral enzymes by binding ...
Lyon have made a last-ditch attempt to lure England and Lions hooker Luke Cowan-Dickie away from Sale Sharks just over a week afte… The 31-year-old is one of eight members of this year’s Rugby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback